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Antibodyoutbreaks of a highly lethal hemorrhagic fever in humans. The virus can be
transmitted by direct contact as well as by aerosol and is considered a potential bioweapon. Because direct
immunization of the respiratory tract should be particularly effective against infection of mucosal surfaces,
we previously developed an intranasal vaccine based on replication-competent human parainﬂuenza virus
type 3 (HPIV3) expressing EBOV glycoprotein GP (HPIV3/EboGP) and showed that it is immunogenic and
protective against a high dose parenteral EBOV challenge. However, because the adult human population has
considerable immunity to HPIV3, which is a common human pathogen, replication and immunogenicity of
the vaccine in this population might be greatly restricted. Indeed, in the present study, replication of the
vaccine in the respiratory tract of HPIV3-immune guinea pigs was found to be restricted to undetectable
levels. This restriction appeared to be based on both neutralizing antibodies and cellular or other
components of the immunity to HPIV3. Surprisingly, even though replication of HPIV3/EboGP was highly
restricted in HPIV3-immune animals, it induced a high level of EBOV-speciﬁc antibodies that nearly equaled
that obtained in HPIV3-naive animals. We also show that the previously demonstrated presence of functional
GP in the vector particle was not associated with increased replication in the respiratory tract nor with
spread beyond the respiratory tract of HPIV3-naive guinea pigs, indicating that expression and functional
incorporation of the attachment/penetration glycoprotein of this systemic virus did not mediate a change in
tissue tropism.
Published by Elsevier Inc.Introduction
Ebola virus (EBOV) causes sporadic outbreaks of severe hemor-
rhagic fever in the rain forests of Central Africa (Nkoghe et al., 2005)
with a lethality in humans of up to 88% for species Zaire (Bulletin
WHO, 1976; Nkoghe et al., 2005). The virus is transmitted by contact
with infected patients or ﬂuids and is thought to enter through breaks
in the skin or inoculation of mucosal membranes (Geisbert and
Jahrling, 2004; Jaax et al., 1995, 1996). The virus also was demon-
strated to infect non-human primates by laboratory generated aerosol
(Johnson et al., 1995) and is considered a potential biological weapon
(Salvaggio and Baddley, 2004). Development of a vaccine for EBOV is a
priority. Two vectored vaccine candidates based on human adenovirus
type 5 and vesicular stomatitis virus and a third candidate based onD, NIH, 50 South Dr. MSC 8007,
nc.a virus-like particle, all delivered parenterally, were shown to be
protective in non-human primates (Jones et al., 2005; Sullivan et al.,
2000; Warﬁeld et al., 2007). We are interested in the general issue of
developing vectors for direct immunization of the respiratory tract,
which frequently can be a portal of infection by highly pathogenic
viruses. The induction of a local immune response in the respiratory
tract would be advantageous for prevention of EBOV transmitted by
contact with respiratory mucosa or by aerosol.
We previously developed an intranasal vaccine candidate against
EBOV (HPIV3/EboGP) based on human parainﬂuenza virus type 3
(HPIV3) as a vector. HPIV3 is an enveloped RNA-containing virus of
Family Paramyxoviridae that is a common cause of human pediatric
disease (Karron and Collins, 2007). Its genome is a single negative-
sense strand of RNA of 15,462 nt that encodes six essential viral
proteins, namely the major nucleocapsid protein N, nucleocapsid
phosphoprotein P, matrix protein M, fusion glycoprotein F, hemagglu-
tinin-neuraminidase glycoprotein HN, and large polymerase protein L.
HPIV3 also encodes accessory C and D proteins from overlapping
open reading frames in the P gene, and there is genetic evidence for
Fig. 1. Replication of HPIV3 and HPIV3/EboGP in nasal turbinates (top panel) and lungs
(bottom panel) of HPIV3-naive guinea pigs. Animals were infected by the intranasal (IN)
routewith 4×105 TCID50 of HPIV3 orHPIV3/EboGP. Animals were sacriﬁced on days 2 (ﬁve
animals per group), 4 (six animals per group), and 7 (ﬁve animals per group) after
inoculation, andnasal turbinates and lungswere isolated and virus titerswere determined.
Mean values are shown±SE with the P values indicated at the top. The limits of detection
are shown by the arrows: 2.11 and 2.15 log10 TCID50/ml for nasal turbinates and lungs,
respectively. When virus was not detected in an individual animal, a value of one-half the
limit of detection was assigned for the purpose of calculation.
256 L. Yang et al. / Virology 377 (2008) 255–264expression of a third protein, V. HPIV3 replicates primarily in the
superﬁcial cells of the lumen of the respiratory tract and remains
largely restricted to that site (Zhang et al., 2005). Using reverse
genetics, one or more open reading frames encoding foreign proteins
can readily be placed under the control of independent sets of HPIV3
gene-start and gene-end transcription signals and inserted into the
HPIV3 gene order (Skiadopoulos et al., 2002). Infection with HPIV3
induces both systemic and local respiratory tract immune responses to
itself and, when used as a vector, to expressed foreign glycoproteins.
Direct inoculation of HPIV3/EboGP into the respiratory tract of HPIV3-
seronegative guinea pigs (Bukreyev et al., 2006b) and African green
monkeys (Bukreyev et al., 2007) resulted in effective induction of
EBOV-speciﬁc serum antibodies and protection against intraperitoneal
challenge with a high dose of EBOV.
We previously noted that the foreign EBOV GP glycoprotein was
incorporated into the HPIV3/EboGP vector particle (Bukreyev et al.,
2006b). Furthermore, it appeared to be functional based on the
observation that the vector partially lost its sensitivity to neutraliza-
tion by HPIV3-speciﬁc antibodies and acquired substantial sensitivity
to neutralization by anti-EBOV antibodies (Bukreyev et al., 2006b). In
animals and humans, EBOV typically establishes a systemic infection
resulting in high EBOV titers in internal organs and blood whereas, in
contrast, HPIV3 is pneumotropic. Since EBOV GP functions in both
attachment and penetration, its incorporation into the HPIV3 vector
particle had the potential to result in an altered tissue tropism with
possible increased replication of the vector in the respiratory tract or
spread of the vector to various tissues beyond the respiratory tract. In
the present study, we evaluated these possibilities in guinea pigs, an
experimental animal that is permissive to both HPIV3 and guinea pig-
adapted EBOV (Bukreyev et al., 2006b).
In addition, we investigated a potential complication of the use
of HPIV3 as a vector. Because HPIV3 is a common human pathogen,
most of the adult human population has substantial immunity due
to prior natural exposure. This prior immunity would be expected
to restrict replication of HPIV3/EboGP, although this effect might
be offset by the presence of functional GP for which the human
population is naive. Reduction in vector replication could greatly
reduce the immunogenicity of the expressed foreign antigen. This
problemwould not be unique to an HPIV3-based vector, since several
current human vaccine candidates are based on viral vectors that
are common human pathogens (reviewed in Bukreyev et al., 2006a).
For example, comparison of immunogenicity of several vaccinia virus-
vectored and human adenovirus type 5-vectored vaccines in pre-
clinical trials with rodents and non-human primates and in clinical
studies demonstrated that preexisting immunity to the vector can
reduce or completely abolish immunogenicity of these vaccines
(Barouch et al., 2004; Casimiro et al., 2003; Fitzgerald et al., 2003;
Kanesa-thasan et al., 2000; Lemckert et al., 2005; Sharpe et al., 2001;
Sumida et al., 2004; Zhi et al., 2006). In particular, induction of EBOV-
speciﬁc cellular and humoral responses by a recombinant adenovirus
type 5 expressing EBOV GP in mice was reduced due to prior expo-
sure to adenoviral vector (Yang et al., 2003). In the present study,
we evaluated replication and immunogenicity of HPIV3/EboGP in
guinea pigs that had recently been infected with HPIV3.We showhere
that, despite restriction of replication of the vaccine by pre-existing
HPIV3-speciﬁc immunity, the expressed EBOV GP remained highly
immunogenic.
Results
Expression and packaging of EBOV GP does not change the tropism of the
HPIV3 vector
We previously showed that expression of the EBOV GP glycopro-
tein by HPIV3/EboGP resulted in the functional incorporation of EBOV
GP into the vector particle (Bukreyev et al., 2006b). This had thepotential of altering the tissue tropism of HPIV3 to confer increased
pulmonary replication or spread of the virus beyond the respiratory
tract. We evaluated these possibilities in guinea pigs, an experimental
animal that supports moderate levels of pulmonary HPIV3 replication,
is very permissive to systemic replication and is readily killed by a low
dose (b1 PFU) of guinea pig-adapted EBOV (Bukreyev et al., 2006b).
Since adaptation of EBOV to guinea pigs does not require mutations in
the GP (Volchkov et al., 2000), guinea pig model should be a sensitive
indicator of EBOV GP-mediated pathogenic effects.
To test the possibility of enhanced pulmonary replication, HPIV3-
seronegative guinea pigs were mock-infected or infected by the in-
tranasal (IN) route with 4×105 50%-tissue-culture-infectious-doses
(TCID50) of HPIV3 or HPIV3/EboGP. On days 2, 4, and 7 after inoculation,
the animals were sacriﬁced, nasal turbinates and lungs were isolated,
and the titers of HPIV3 or HPIV3/EboGP in the tissue extracts were
determined by TCID50 titration on LLC-MK2 cell monolayers (Fig. 1). The
data showed that HPIV3 efﬁciently replicated in both the upper and the
lower respiratory tract with the highest virus titer detected on day 2, a
somewhat lower titer on day 4, and little or no detectable virus on day 7.
Compared to HPIV3, the HPIV3/EboGP virus replicated at similar or
slightly reduced levels, dependingon the location and timepoint (Fig.1).
We also evaluated the presence of viral antigen in the lower res-
piratory tract by immunohistochemistry. HPIV3-seronegative guinea
257L. Yang et al. / Virology 377 (2008) 255–264pigs were infected with HPIV3 or HPIV3/EboGP as above, sacriﬁced on
day 2, and the lungs were harvested and stained for HPIV3 antigenwith
polyvalent anti-HPIV3 antibodies raised against sucrose gradient-
puriﬁed HPIV3 (Fig. 2). For both HPIV3- and HPIV3/EboGP-infected
animals, viral antigen (stained brown) was detected in bronchi and
bronchioles extending into inﬂammatory alveolar lesions. For both
viruses, a moderate amount of antigen was detected in the bronchi
(Figs. 2, A and B), less was detected in smaller airways (C and D), and
even less in the alveoli (E and F). Generally, less antigenwas detected in
HPIV3/EboGP-infected animals compared to that in the HPIV3 control
animals. Thus, there was evidence of attenuation rather than increased
spread associated with expression of EBOV GP.Fig. 2. Immunohistochemical analysis of HPIV3 antigen distribution (brown) in the respirator
with hematoxylin counterstain (blue). A, B. Diffuse (HPIV3) and focal (HPIV3/EboGP) infectio
alveolar interstitial lesions, 400×
^
. No antigen was detected in the lung tissues of mock-infecNext, we tested the possibility that HPIV3/EboGP might spread
to tissues beyond the respiratory tract. Groups of seronegative
guinea pigs were inoculated with HPIV3 or HPIV3/EboGP. Two and
four days after inoculation, the animals were sacriﬁced and samples
of the peripheral blood, liver, kidney and spleen were collected.
The peripheral blood samples and the tissue extracts were tested
for presence of infectious virus by the limiting dilution assay as
described above. Virus was not detected in any of the samples (not
shown). Taken together, these data indicate that the presence of
EBOV GP in the vector particles did not confer enhanced replica-
tion or promote spread of the HPIV3 vector beyond the respiratory
tract.y tract of guinea pigs infectedwith HPIV3 (panels A, C, E) or HPIV3/EboGP (panels B, D, F),
n of bronchial epithelial cells, 200×
^
. C, D. Infection in bronchioles, 400×
^
. E, F. Infection in
ted animals (not shown).
Fig. 3. Replication of HPIV3 and HPIV3/EboGP in A549 cells in the presence of antibodies
speciﬁc to HPIV3. Cell monolayers were infected at an input MOI of 0.
^
001 PFU/cell and
the subsequent incubation
^
were performed in the presence or absence of neutralizing
polyvalent HPIV3-speciﬁc antibodies. A. Analysis of infectious virus production. Aliquots
of medium were collected daily and viral titers were determined by plaque titration.
B. Analysis of intracellular viral proteins as an indication of virus replication. Cells were
collected on days 3 and 5 post infection and total proteinwas subjected toWestern blot
analysis with polyvalent HPIV3-speciﬁc antiserum. Equal amounts of cells lysates were
loaded on the gel. On day 5, the infectedmonolayerswith no antibodieswere completely
destroyed by the viruses and therefore were not analyzed. Two bands corresponding to
HPIV3 proteins P and N are shown. Lanes: 1, 10, Magic Mark XP protein markers with
bands corresponding to 80 kDa and 60 kDa; 2, 4, 7, HPIV3-infected cells; 3, 5, 8, HPIV3/
EboGP-infected cells; 6, 9, mock-infected cells. The HPIV3-speciﬁc neutralizing
antibodies were present in the medium of cells analyzed in lanes 4, 5, 7, and 8.
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Since incorporation of the EBOV GP protein into the recombinant
HPIV3 vector was previously observed to reduce its sensitivity to
neutralization by HPIV3-speciﬁc antibodies in vitro (Bukreyev et al.,
2006b), it was possible that this would enhance its ability to replicate
in vitro and in vivo in presence of the HPIV3-speciﬁc immunity. This
was evaluated in vitro by infecting replicate cultures of A549 cells with
HPIV3orHPIV3/EboGPat amultiplicity of infection (MOI) of 0.001 PFU/
cell and, after an 80 min adsorption period, incubating the cultures
with medium containing a 1:100 dilution of polyvalent HPIV3-speciﬁc
antiserum. The cultures were incubated at 32 °C and aliquots of the
overlying medium were collected daily for virus titration by plaque
assay. In cultures where the antiserum had not been added, each virus
replicated efﬁciently (Fig. 3A, top). In cultures incubated in the pre-
sence of antiserum, HPIV3 was not detected on days 1–5, and only a
very low, barely detectable titer was detected on day 6. In contrast,
HPIV3/EboGP was recovered in the presence of anti-HPIV3 antibodieswith titers ranging from 3.5 to 4.7 log10 PFU/ml (Fig. 3A, bottom),
although these titersweremuch lower than that in the cells containing
no antibodies (Fig. 3A, top). To conﬁrm that this represented increased
infection of the cell monolayers, cells were harvested on days 3 and 5
and were subjected to Western blot analysis with HPIV3-speciﬁc
antiserum. This showed that, in the absence of HPIV3-speciﬁc anti-
serum in the medium, there was an abundant level of cell-associated
HPIV3 proteins in cultures infected with either HPIV3 or HPIV3/EboGP,
as expected (Fig. 3B, lanes 2 and 3). With the inclusion of HPIV3-
speciﬁc antiserum, the level of intracellular HPIV3 protein was dra-
matically reduced for both HPIV3 and HPIV3/EboGP, an effect that was
greater for HPIV3 than HPIV3/EboGP (Fig. 6, lanes 4 versus 5 and 7
versus 8). Thus, while HPIV3/EboGP was somewhat resistant to neu-
tralization byHPIV3-speciﬁc antiserum,multi-cycle infection byeither
virus was strongly inhibited by HPIV3-speciﬁc antibodies.
Next, we tested the ability of the vaccine construct to replicate in
animals immune to theHPIV3vector. Guineapigsweremock-infectedor
infected by the IN routewith 4×105 TCID50 of HPIV3, and serum samples
were collected 36days later. As expected, all of the animals that received
HPIV3 developed strong HPIV3-speciﬁc antibody responses as mea-
sured by an HPIV3-speciﬁc hemagglutination-inhibition (HAI) assay
(van Wyke Coelingh et al., 1985), and all mock-infected animals re-
mained HPIV3-seronegative (average reciprocal titers of 9.9±0.1 log2
and b2 log2, respectively). On day 40 after the primary infection, the
animals were infected by the IN route with 4×106 TCID50 of HPIV3 or
HPIV3/EboGP. On days 2, 4, and 7 after the second infection, animals
were sacriﬁced, nasal turbinates and lungs were isolated, and the titers
of HPIV3 or HPIV3/EboGP in the tissue extracts were determined as
described above. Virus was not detected on any tested day for any virus
in either the nasal turbinates or the lungs (data not shown), indicating
that replication was strongly restricted in HPIV3-immune animals.
Restriction of HPIV3/EboGP replication in vivo is mediated by neutralizing
antibodies and cellular or other components of the immune response
Next, we evaluated whether the restriction of HPIV3/EboGP re-
plication in HPIV3-immune animals was mediated by the humoral or
cellular component of the immune response, and whether there was
a difference between HPIV3 and HPIV3/EboGP. This was done by
measuring the restriction conferred by prior infectionwith HPIV3-1, a
chimeric HPIV3 virus in which the two surface glycoproteins, HN and
F, were replaced with their counterparts from serologically unrelated
HPIV1, and which replicates in vitro and in vivo as efﬁciently as wild
type HPIV1 and HPIV3 (Tao et al., 1998). The HN and F proteins are the
only HPIV antigens that induce neutralizing antibodies (Karron and
Collins, 2007), and there is no cross-protection in vivo between HPIV3
and HPIV1 (Tao et al., 2000); thus, any HPIV3-speciﬁc immunity
induced by HPIV3-1 would involve only the internal virion proteins,
would not involve neutralizing antibodies, and presumably would
primarily involve cellular immunity (Tao et al., 1998). As a caveat, we
cannot exclude the possibility that the internal proteins of HPIV3
might induce antibodies that do not neutralize the virus in vitro but
might restrict replication in vivo; such antibodies have been described
for several viruses, including rotavirus (Burns et al., 1996; Feng et al.,
2002) and Sindbis virus (Mendoza et al., 1988), although not for HPIV3
thus far.
Guinea pigs were infected by the IN route with 4×105 TCID50 of
HPIV3 or HPIV3-1, or were mock-infected, and serum samples were
collected on day 27 and assayed for HPIV3-speciﬁc HAI antibodies.
Infectionwith HPIV3 resulted in a reciprocal antibody titer of 11.7±0.4
log2, whereas there was no detectable HPIV3-speciﬁc response in
HPIV3-1-infected or mock-infected animals (reciprocal titer b2 log2).
We also analyzed these sera for the ability to neutralize HPIV3 and
HPIV3/EboGP using an in vitro plaque reduction assay. This showed
that sera from animals infected with HPIV3 completely neutrali-
zed HPIV3 and incompletely neutralized HPIV3/EboGP, as previously
Fig. 4. Replication of HPIV3 and HPIV3/EboGP in the nasal turbinates (left panels) and lungs (right panels) of guinea pigs that had previously been mock-infected or infected with
HPIV3 or HPIV3-1, as indicated. The initial infection with HPIV3 or HPIV3-1 was at a dose of 4×105 TCID50. The second infection with HPIV3 or HPIV3/EboGP was
^
42 days later at a
dose of 4×106 TCID50. The animals (four per virus per day) were sacriﬁced
^
2 days later and nasal turbinates and lungs were isolated and used (A) for virus titration and (B) for isolation
of total RNA and comparison of viral RNA concentrations by quantitative RT-PCR. In part A, the limits of detection (same as in Fig. 1) are indicated with arrows. The values represent
(A) mean viral titers or (B) mean threshold cycle (Ct)±SEwith the P values indicated at the top. For quantitative RT-PCR of HPIV3/EboGP RNA in lungs of HPIV3-immune animals, three
rather then four animals were analyzed.
259L. Yang et al. / Virology 377 (2008) 255–264described (Introduction, and Bukreyev et al., 2006b), whereas neither
virus was neutralized with the sera from HPIV3-1-immunized or
mock-immunized animals (data not shown). Thus, the expected
speciﬁcities were conﬁrmed. Forty-two days after the primary
infection, we challenged the animals by the IN route with 4×106
TCID50 of HPIV3 or HPIV3/EboGP. Two days after the second infection
(which is the peak of viral replication in a primary infection, as
shown in Fig. 1), the animals were sacriﬁced, and nasal turbinates and
lungs were analyzed for presence of virus. Similar to the previous
experiment, animals that had been mock-infected and challenged had
equally high titers of HPIV3 and HPIV3/EboGP in both the lungs and
nasal turbinates (Fig. 4A). In animals that had been immunized with
HPIV3 and challenged, neither challenge virus was detected in either
location (Fig. 4A). In contrast, in animals that had been immunized
with HPIV3-1 and challenged, the HPIV3 and HPIV3/EboGP challenge
viruses replicated in the nasal turbinates to levels that were ap-
proximately equivalent and were signiﬁcantly reduced compared to
that in animals that were initially mock-infected. In the lungs of
HPIV3-1 immune animals, there was no detectable HPIV3/EboGP and
only a low level of HPIV3 challenge virus (Fig. 4A).
In order to conﬁrm that the reduction of the HPIV3/EboGP titers in
HPIV3- or HPIV3-1-immune animals was an authentic in vivo effect
and not the result of neutralization in vitro by HPIV-speciﬁc antibodies
following harvest and tissue homogenization, we performed HPIV3 Nand HN gene-speciﬁc quantitative reverse transcription (RT)-PCR
assays using RNA extracted from the nasal turbinates and lung tissue
samples. In this assay, the threshold cycle (Ct) is the number of cycles
required for ampliﬁcation of a sample into a detectable signal, and
thus would be low for samples with high viral titers as determined by
TCID50 assay and would be high for low-titer samples. The results of
the N gene-speciﬁc assay are shown in Fig. 4B. Similar to the virus
titration results (Fig. 4A), there was no signiﬁcant difference in Ct
between the two challenge viruses (HPIV3 and HPIV3/EboGP) in
either of the immunization groups (HPIV3 and HPIV3-1) and at either
anatomical location. In addition, the Ct values of the HPIV3-
immunized groups were signiﬁcantly higher than those of the mock
groups, and the Ct values of the HPIV3-1 groups were signiﬁcantly
lower than those of the HPIV3 groups, and greater (although not
signiﬁcantly so) than the mock groups. Similar data were obtained
with the HN gene-speciﬁc assay (not shown). Thus, on the basis
of virus titration, HPIV3-1 was less protective than HPIV3 against
HPIV3 and HPIV3/EboGP replication in the nasal turbinates, whereas
there was no difference in the lungs (Fig. 4A), and on the basis of
quantitative RT-PCR HPIV3-1 was less protective than HPIV3 at both
locations.
The substantial but incomplete protection provided by HPIV3-1
compared to HPIV3 indicated that both the surface and the internal
proteins of HPIV3 make contributions to restricting both HPIV3 and
Fig. 5. Immunogenicity of HPIV3/EboGP in guinea pigs that had previously been
infected with HPIV3 or HPIV3/EboGP. Top panel: map of the experiment. The numbers
in parentheses refer to the days after the second infection, and the symbols (dotted,
cross-hatched, black) match those in the graphs below. Antibody responses: the anti-
HPIV3 titers determined by HAI (middle panel) and the anti-EBOV titers determined by
ELISA (bottom panel) from sera collected on day 42 following the ﬁrst infection (dotted
bars), and days 28 (cross hatched) and 42 (black) following the second infection. The
antibody titers are expressed as reciprocal log2 of endpoint dilutions and shown as
mean titers±SE with the P values indicated at the top. Indicated at the bottom are: the
group numbers (1 to 6) and the virus and dose used for the ﬁrst and the second
infections. Groups 1, 3 and 5 contained 10 animals each, and groups 2, 4 and 6 included
12 animals each. On day 42, the HPIV3-speciﬁc antibody titers in groups 3 and 4 were
below the detection limit of the HAI assay (which is 2 log2), and are indicated with
asterisks.
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exclude a possible contribution by antibodies not detectable by an in
vitro neutralization assay, it seems likely that cellular immunity made
the major contribution to this effect. In addition, the ﬁnding that
HPIV3/EboGP was at least as restricted as HPIV3 by prior immunity to
HPIV3-1 is a further indication that expression and incorporation of
the foreign GP did not confer increased replication or substantial
escape fromHPIV3-speciﬁc immunity, in this case mediated by factors
other than neutralizing antibodies.Despite the lack of detectable replication, HPIV3/EboGP is highly
immunogenic in HPIV3-immune animals
As noted in the Introduction, there are several instances of
experimental vectored vaccines in which pre-existing immunity to the
vector reduced or blocked the immune response to the expressed
foreign antigen. Therefore, we compared the ability of HPIV3/EboGP to
induce a serum antibody response to EBOV GP in guinea pigs that either
possessed or lacked prior immunity to HPIV3. Following the experi-
mental scheme in Fig. 5 (top panel), guinea pigs were infected by the IN
route with 4×105 or 4×106 TCID50 of HPIV3, 4×106 TCID50 of HPIV3/
EboGP, or were mock-infected, and serum samples were collected on
day 42 after infection. Forty-nine days after the ﬁrst infection, animals
received a second infection by the IN routewith 4×106 TCID50 of HPIV3,
HPIV3/EboGP, or weremock-infected. Serum samples were collected 28
and 42 days after the second infection. All serumsampleswere analyzed
forHPIV3-speciﬁc antibodies byHAI (Fig. 5,middle panel) and for EBOV-
speciﬁc antibodies by enzyme-linked immunoadsorbent assay (ELISA)
against inactivated, disrupted EBOV (bottom panel).
As expected, following the primary infection with HPIV3 (Fig. 5,
middle panel, groups 1, 2, and 5) or HPIV3/EboGP (group 6), all of the
animals developed an HPIV3-speciﬁc serum antibody response. In
animals infected with HPIV3, the reciprocal titer of antibodies reached
10.1±0.4 log2 after infection with 4×105 TCID50 (groups 1 and 2) and
10.4±0.2 log2 after infection with 4×106 TCID50 (group 5). In com-
parison, infectionwith 4×106 TCID50 of HPIV3/EboGP (group 6) induced
a lower HPIV3-speciﬁc antibody titer of 7.0±0.2 log2 (Pb0.001). This
might reﬂect the somewhat reduced replication of HPIV3/EboGP com-
pared to HPIV3, as was observed in Fig. 1, as well as a possible reduction
of the density of the HN protein on the surface of the viral particles due
to incorporation of the GP protein (Bukreyev et al., 2006b). In any event,
this difference largely disappeared with time, such that the titer of
HPIV3-speciﬁc antibodies in the group that received a single dose of
HPIV3/EboGP (group 6) was nearly the same at 77 or 91 days following
the day 0 infection as in animals that received a single dose of HPIV3
(group 5).
Similar to the previous experiments, animals that weremock-infected
and subsequently infectedwith HPIV3/EboGP (Fig. 5, bottompanel, group
4) developed high titers of serum antibodies speciﬁc for EBOV that, based
on previous work, would be associated with complete protection against
challenge with a highly lethal dose of EBOV (Bukreyev et al., 2006b).
Surprisingly, a strong serum antibody response to EBOV was achieved
even in animals that were previously infected with HPIV3 (group 2):
the EBOV-speciﬁc antibody titer achieved in HPIV3-immune animals
(group 2)was only slightly less than that achieved in non-HPIV3-immune
animals (group 4) on day 28 following the second infection, and was
essentially equivalent on day 42. These data indicate that, despite the
restriction of HPIV3/EboGP replication in HPIV3-immune animals, the
vaccine construct was highly immunogenic. In addition, we also observed
a signiﬁcant increase over time in the titer of EBOV-speciﬁc antibodies in
animals that received a single dose of HPIV3/EboGP on day 0 (group 6):
speciﬁcally, on days 77 and 91, the titers were increased 2.1-fold and 3.5-
fold, respectively, compared to day 42. Thus, the response increased rather
than decreased with time during this three-month interval.
Immunogenicity of HIV3/EboGP depends on its replication
Since EBOV GP is incorporated into the HPIV3/EboGP particle, it
was possible that the GP-speciﬁc immune response induced by HPIV3/
EboGP in HPIV3-immune animals was due to preformed GP contained
in the inoculum. Thus, we investigated whether the immune response
to EBOV GP depended on the replication of HPIV3/EboGP. We im-
munized four guinea pigs by the IN route with 4×106 TCID50 of HPIV3/
EboGP and another four animals with UV-inactivated HPIV3/EboGP.
The UV dose had been pre-calibrated to be the minimum necessary to
inactivate infectivity, which was done to minimize the possibility that
Fig. 6. Effect of replication and route of immunization on the immunogenicity of HPIV3/
EboGP. A. Effect of replication. Guinea pigs (four animals per group) were infected IN
with HPIV3/EboGP at a dose of 4×106 TCID50 or with an equivalent amount of UV-
inactivated virus. Serawere collected 29 days post-infection and the titers of HPIV3- and
EBOV-speciﬁc serum antibodies were determined by HAI and ELISA respectively. Serum
antibody titers are expressed as reciprocal log2 of endpoint dilutions and shown as
mean titers±SE with the P values indicated at the top. In sera of mock-infected animals
(representing 5 animals from a separate experiment), the level of HPIV3-speciﬁc
antibodies was below the detection level (2 log2), and is indicated with an asterisk. In
the HPIV3/EboGP-UV group, the level of HPIV3-speciﬁc antibodies in three out of four
animals was below the detection level, and the value of 2 log2 was assigned for
calculation purposes. The detection limit of the HAI assay is 2.0 log2. B. Effect of the IN
versus IM route of immunization. Guinea pigs were immunized with 4×106 TCID50 of
HPIV3/EboGP by the IN or IM route (six animals per group), or 4×106 TCID50 of HPIV3 by
the IM route (three animals). Sera were collected on day 30 after immunization and the
titers of HPIV3- and EBOV-speciﬁc serum antibodies were determined as above. In
addition, sera from nine animals collected on day 28 after IN infection with 4×106
TCID50 of HPIV3 from a previous experiment (Fig. 5) were analyzed in parallel for
comparison. In an uninfected group (which consisted of two animals from a separate
experiment), the level of HPIV3-speciﬁc antibodies was below the detection level, and is
shown with an asterisk. In the HPIV3-immunized group, the level of EBOV-speciﬁc
antibodies was below the detection level and is shown with a plus. The detection limit
of the HAI assay was 5.32 log2.
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Twenty-nine days after inoculation, serum samples were collected
and analyzed for the presence of serum antibodies speciﬁc to HPIV3 or
EBOV as above. As in the previous experiments, all of the animals
immunized with infectious HPIV3/EboGP developed high titers
of serum antibodies speciﬁc for both HPIV3 and EBOV (Fig. 6A). In
contrast, three of the four animals immunized with UV-inactivated
HPIV3/EboGP remained HPIV3 seronegative while the remaining
animal had a low level HPIV3-speciﬁc antibodies (titer 1:64). With
regard to the EBOV-speciﬁc response, animals immunized with UV-
HPIV3/EboGP had only very low levels of antibodies to EBOV.
The poor immunogenicity of UV-HPIV3/EboGP in HPIV3-naive
animals (Fig. 6A) suggested that the strong EBOV-speciﬁc responses toHPIV3/EboGP in HPIV3-immune animals (Fig. 5) depended on HPIV3/
EboGP replication even though infectious progeny virus was not
detected in the nasal turbinates and lung tissues (Fig. 4A). However, it
alsowas conceivable that, in the HPIV3-immune animals, an antibody-
mediated enhancement occurred independent of replication, such as
through capture of antibody-virus complexes by dendritic cells and
macrophages. To investigate this, we infected or mock-infected groups
of guinea pigs by the IN route with 4×105 TCID50 of HPIV3. Forty-two
days later, the animals were immunized by the IN route with 4×106
TCID50 of HPIV3/EboGP or with an equivalent amount of UV-HPIV3/
EboGP. In both HPIV3-immune and non-immune animals, HPIV3/
EboGP induced strong EBOV-speciﬁc antibody responses, as already
seen, whereas the response to UV-HPIV3/EboGP was marginal (like
that in Fig. 6A) and was not different between the immune and non-
immune animals. These data suggest that pre-existing HPIV3-speciﬁc
antibodies did not enhance the immunogenicity of UV-HPIV3/EboGP.
Immunogenicity of HIV3/EboGP depends on inoculation through the
respiratory tract
As already noted, whereas HPIV3 infects the superﬁcial cells of the
respiratory tract and typically does not spread signiﬁcantly beyond
that site, EBOV causes a systemic infection. Although there was no
detectable spread of viable HPIV3/EboGP to the blood, spleen, liver
and kidneys following IN inoculation, it alsowas important to evaluate
whether systemic infection might occur following inoculation by a
parenteral route. To test this possibility, we infected six guinea pigs
with HPIV3/EboGP by the IN route, six animals with HPIV3/EboGP by
the IM route, and three animals with HPIV3 by IM route, using a dose
of 4×106 TCID50 in each instance. Thirty days after immunization,
serum samples were collected and analyzed for presence of antibodies
speciﬁc for HPIV3 and EBOV as above. For comparison, sera from
animals that had been infected IN with the same dose of HPIV3 in a
previous experiment were examined in parallel.
The HPIV3-speciﬁc responses to IM infection with either virus
were readily detectable and were only marginally reduced compared
to IN infection (Fig. 6B, left panel). This was not surprising, since IM
inoculation with respiratory syncytial virus had previously been
shown to induce a titer of neutralizing serum antibodies that was one-
third that of the high titer induced by IN infection, apparently
reﬂecting an abortive replicative cycle at the site of IM injection
(Prince et al., 1979). In contrast, IM infection with HPIV3/EboGP
resulted in only a low level of EBOV-speciﬁc serum antibodies, with
the average magnitude of 3.5±0.9 log2, that was 114-fold lower than
that in the control animals immunized through the IN route in the
same experiment (Fig. 6B, right panel). The reduced immunogenicity
of HPIV3/EboGP given parenterally was interpreted as an indication
that the virus did not efﬁciently infect cells or did not efﬁciently
replicate following parenteral administration. The substantial res-
ponse speciﬁc to HPIV3 HN detected by the HAI assay may reﬂect an
unusually high immunogenicity of this protein. The lack of signiﬁcant
EBOV-speciﬁc response following the IM infection supports the idea
that HPIV3/EboGP had a reduced rather than increased capability to
replicate systemically, and also is consistent with the idea that the
amount of protein contained in the inoculum is insufﬁcient to be
signiﬁcantly immunogenic on its own in naive animals.
Discussion
In this study, we evaluated the safety, replication, and immuno-
genicity of an intranasal HPIV3-vectored vaccine against EBOV in
guinea pigs in the presence or absence of prior immunity to the HPIV3
vector. When HPIV3/EboGP was administered IN to non-immune
animals, high levels of virus replication occurred and resulted in
robust serum antibody responses to both the vector and the insert.
The animals were not challenged with EBOV in this particular study,
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antibodies are associated with a uniform protection against a highly
lethal dose of EBOV (Bukreyev et al., 2006b). In the present study, we
also showed that pulmonary replication of HPIV3/EboGP was slightly
reduced compared to its HPIV3 parent, and that infectious virus could
not be detected in the peripheral blood or in the liver, kidney, and
spleen. In addition, parenteral inoculation with HPIV3/EboGP did not
induce signiﬁcant levels of serum antibodies to EBOV. Thus, even
though EBOV GP was incorporated into the vector particle and
conferred resistance to HPIV3-speciﬁc antibodies and sensitivity to
EBOV-speciﬁc antibodies (evidence that it was functional in initiating
infection), this did not result in increased pulmonary replication nor
did it confer the ability to spread to and replicate detectably in
peripheral tissues. This is noteworthy since EBOV GP mediates both
viral attachment and entry, and thus would have the potential to alter
tropism on its own. Guinea pigs are highly permissive to replication of
guinea pig-adapted EBOV (which, as noted above, not require
mutations in GP) and are very sensitive to virus-induced disease and
death, and thus provided a sensitive test for increased pathogenicity
due to EBOV GP. These ﬁndings form a precedent that is of general
usefulness and relevance with regard to the issue of the biological
safety of recombinant vectors the express foreign surface proteins and
incorporate these proteins in the vector particle.
When HPIV3/EboGP was administered IN to HPIV3-immune animals,
infectious virus could not be detected in nasal turbinate and lung tissues
harvested on days 2, 4, and 7 following infection. This restriction of
replicationwasmediatedbyboth the antibodyand cellular components of
the immune response, which was determined using animals that had
been immunized with a chimeric HPIV3-1 virus that expresses the
“internal” proteins of HPIV3 and the surface neutralization antigens of
HPIV1. Surprisingly, despite the lack of detectable replication of HPIV3/
EboGP in the respiratory tract, its immunogenicity was essentially the
same as that observed in HPIV3-naive animals, which is sufﬁcient for
protection against EBOV challenge (Bukreyev et al., 2006b). One caveat is
thatwedidnot directlymeasure cell-mediated responses toHPIV3/EboGP
in HPIV3-immune animals, due to a lack of available reagents. Therefore,
we cannot rule out the formal possibility that the cellular immune
response was substantially reduced in HPIV3-immune animals. However,
evenwithout any contribution from cell-mediated immunity, the levels of
EBOV-speciﬁc serum antibodies that were achieved would be consistent
with substantial protection. In the present study, the mean reciprocal
ELISA titers of EBOV-speciﬁc serum antibodies were approximately
1:3500 on day 28 and 1:7500 on day 42. Previous studies showed that
passive EBOV-speciﬁc antibodies alone can provide substantial protection
against EBOV challenge. In one study, guinea pigs were infected
intraperitoneallywith EBOVand immediatelygivenEBOV-speciﬁc passive
antibodies by the subcutaneous route. A dose of antibodies that conferred
a serumELISA titer of 1:80–1:160whenmeasured twodays later provided
complete protection against the day 0 infectionwith 10,000 PFU of guinea
pig-adapted EBOV (Jahrling et al., 1999). In a comparable experiment in
mice, a dose of antibodies that conferred a serum ELISA titer of ap-
proximately 1: 6400 when measured on day 1 provided high level pro-
tection against a day 0 challenge with 1000 PFU of EBOV (Gupta et al.,
2001). This suggests that the response achieved by HPIV3/EboGP in
HPIV3-immune animals in the present study would be protective.
These data contrasted with studies involving other vector systems,
in which the immunogenicity of human adenovirus type 5-vectored
and vaccinia virus-vectored vaccines was signiﬁcantly reduced or
completely abolished by the presence of the vector-speciﬁc immunity
(see Introduction). The mechanism by which the immunogenicity
of these latter vectors is reduced in immune animals is unknown,
but might include neutralization of the vector inoculum, more rapid
destruction of vector-infected cells, and neutralization of progeny
vector in the case of replication-competent vectors.
Several mechanisms by which HPIV3/EboGP retained its immuno-
genicity in HPIV3-immune animals can be suggested. One possibilitywas that the presence of functional EBOV GP in the vector particle
conferred increased infectivity and spread inHPIV3-immune animals. In
monolayer cell culture, we found that HPIV3/EboGP indeed was more
resistant than HPIV3 to neutralization by HPIV3-speciﬁc antibodies and
had a somewhat greater ability to spread under those conditions.
Although this effect was modest under the conditions that were tested
in vitro, it might be sufﬁcient to confer increased immunogenicity in
vivo. In addition, the IN route of administration might play a role in
the ability to immunize despite pre-existing immunity to the vector.
Speciﬁcally, the effectiveness of host immunity in the respiratory tract
characteristically is incomplete due to the short-lived nature of mucosal
immunity following a primary infection, the inefﬁciency by which
serum antibodies gain access to the respiratory lumen, and the func-
tional impairment of cytotoxic T lymphocytes in the lung (Vallbracht
et al., 2006). In addition, certain respiratory viruses such as the HPIVs
and respiratory syncytial virus seem particularly able to partially evade
host immunity and establish symptomatic re-infections whereas other
respiratory viruses such as inﬂuenza virus and adenovirus are more
strongly restricted by prior immunity. Although the basis behind the re-
infectability of viruses such as HPIV3 is poorly understood, this may
contribute to the effect observedhere. A recent study showed that,when
cotton rats that were immune to respiratory syncytial virus were re-
infected with the virus, the level of intracellular viral RNA synthesis
during the ﬁrst 12–24 h of infection was nearly as high as in non-
immune animals even though no infectious progeny virus was detected
in the immune animals throughout the infection (Boukhvalova et al.,
2007). Thus, prior immunity did not seem to restrict infection and
the initial viral replicative cycle, which presumably would result in
substantial antigen synthesis. In this context, it is noteworthy that a
recent study demonstrated that activation of respiratory dendritic cells
takes place within the ﬁrst 24 h after infection of mice with inﬂuenza
virus (Legge and Braciale, 2003), which is long before the peak of the
virus replication in lungs. After that, respiratory dendritic cells become
refractory to stimulation by the virus (Legge and Braciale, 2003).
Therefore, the effective presentation of EBOV antigenmay dependmore
on the initial infectability and initial replicative cycle of the virus and be
less dependent on the magnitude of subsequent replication.
We had previously assumed that HPIV3-based vectors would not
be sufﬁciently immunogenic in adolescents and adults due to the
prevalence of immunity to this common human pathogen. However,
the present study suggests that use of the pneumotropic HPIV3 vector
and the topical route of immunization may provide for substantial
immunization in immune individuals. Indeed, if the vector is res-
tricted by host immunity but is nonetheless immunogenic, vaccine
safety would be increased. However, it will be essential to conﬁrm that
HPIV3/EboGP is immunogenic in HPIV3-immune non-human pri-
mates, which are anatomically and phylogenetically more closely
related to humans. That would be followed by clinical trials, which in
the interest of safety would employ an attenuated version of HPIV3 as
vector. Several such attenuated versions have been or presently are in
clinical trials as pediatric intranasal HPIV3 vaccine candidates
(Murphy and Collins, 2002). Since non-human primates are less
permissive than humans to HPIV3 replication, results obtained in non-
human primates using wild type HPIV3 as vector may be comparable
to what would be observed in humans using an attenuated derivative
as vector. We also are developing chimeric viruses in which the HN
and F proteins of the HPIV3 vector are deleted and replaced by GP. This
would provide a vector that would not be neutralized by HPIV3-
speciﬁc antibodies against the major HN and F antigens. While
this chimeric virus would remain sensitive to HPIV3-speciﬁc cellular
immunity directed against “internal” HPIV3 proteins, that immune
component is much less long-lived than neutralizing antibodies and
likely would be less effective in restricting the vector. Finally, use of
non-human respiratory paramyxoviruses such as Newcastle disease
virus as a platform for intranasal vaccine against EBOV may also be a
promising approach (Bukreyev et al., 2005).
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Viruses, cells, animals, and HPIV3-speciﬁc antiserum
Recombinant wild type HPIV3 and HPIV3/EboGP used in this study
have been described previously (Bukreyev et al., 2006b; Durbin et al.,
1997). UV-inactivation of HPIV3/EboGP was performed with a UV
Stratalinker 1800 (Stratagene, La Jolla, CA) using a UV dose of 128 mJ,
which was determined to be theminimumdose required for complete
inactivation of infectivity of the preparation. Rhesus monkey kidney
LLC-MK2 and human A549 type II alveolar adenocarcinoma cells
(AmericanType Culture Collection, Manassas, VA)were grown in Opti-
MEM medium containing 2.5% fetal bovine serum (both from
Invitrogen, Carlsbad, CA). HPIV3 and HPIV3/EboGP were grown and
titrated in LLC-MK2 cells. Guinea pigs (strain Hartley, four to thirteen
weeks old) were obtained from Charles River Laboratories (Wilming-
ton, MA) and conﬁrmed to be seronegative for HPIV3 by HAI using
guinea pig erythrocytes (vanWyke Coelingh et al.,1985). For intranasal
(IN) inoculation, animals were anesthetized by inhalation of methoxy-
ﬂurane (Medical Developments International Limited, Springvale, Aus-
tralia), and 100 μl of a viral suspension in Leibowitz L-15 medium
(Invitrogen) was applied to each nostril. Intramuscular (IM) inocula-
tions involved 100 μl of a viral suspension in L-15 medium per animal.
To isolate internal organs or tissue samples, the animalswere sacriﬁced
by carbon dioxide inhalation. All procedures were performed in accor-
dance with protocols and guidelines approved by the NIH Animal Care
and Use Committee and were performed in a facility approved by the
Association for Assessment and Accreditation of Laboratory Animal
Care International. Polyvalent HPIV3-speciﬁc antiserumwas prepared
by hyperimmunizing rabbits with sucrose gradient-puriﬁed HPIV3.
Quantitative analysis of the viruses in animal tissues
Harvested tissues were weighed, homogenized in L-15 medium
(Invitrogen) using Omni TH tissue homogenizer with disposable tips
(Omni International, Marietta, GA) and clariﬁed by low-speed centrifuga-
tion, and the resulting tissue suspensions were aliquoted and stored at
−80 °C until virus titration. Virus titers were determined by limiting
dilution in LLC-MK2 cells and expressed as TCID50. In some cases, plaque
titrations in LLC-MK2 cells also were performed, as previously described
(Bukreyev et al., 2006b). For quantitative RT-PCR, total RNA was isolated
from the tissue extracts using RNeasy mini kit (Qiagen, Valencia, CA)
according manufacturer's recommendations, subjected to reverse tran-
scription reaction with random hexamers and analyzed with TaqMan
GeneExpressionAssay (AppliedBiosystems, FosterCity, CA). The following
sets of primers and probes were designed and produced by Applied
Biosystems: HPIV3 N gene-speciﬁc set, forward primer 5′-CGGTGACA-
CAGTGGATCAGATT-3′, reverse primer 5′-TGTTTCAACCATAAGAGTTAC-
CAAGCT-3′, probe 5′-ACCGCATGATTGACCC-3′; HPIV3 HN-speciﬁc set,
forward primer 5′-CACAAACACGTGCAAATTTTACACT-3′, reverse primer
5′-AGTTGCAGTATCCTTTAATCTGTGTGAT3′-, probe 5′-CCGGTGTTAAAATT-
TT-3′. In some cases, nasal turbinate and lung samples from HPIV3-
immune animals were negative for viral RNA due to the high level of
protection: these samples were assigned a Ct value of 40, which was the
limit of detection, in order to calculate mean Ct±SE.
Immunohistochemical analysis of animal tissues
Lung tissues were ﬁxed in neutral buffered formalin and embedded
in parafﬁn, and sectionswere cut at 4–5 μm. The sectionsweremounted
on positively charged slides. Antigen retrieval from parafﬁn sections
was performed in a food steamer (Sunbeam, Boca Raton, FL) with Diva
decloaker solution (Biocare, Concord, CA). Immunostaining for HPIV3
antigens was performed using a 1:500 dilution of HIPV3-speciﬁc poly-
clonal antibodies and the Dako Envision rabbit HRP (DAB+) kit with HRP
labeled polymer (Dako, Carpenteria, CA).Analysis of antibody responses
HPIV3-speciﬁc serum antibody responses were determined by the
above-mentioned HAI assay (van Wyke Coelingh et al., 1985). EBOV-
speciﬁc serum antibody responses were determined by ELISA against
EBOV particles that had been inactivated with gamma radiation, pu-
riﬁed, and disruptedwith Tween 20 (Bukreyev et al., 2006b). For Fig. 5,
the assay was performed exactly as previously described (Bukreyev
et al., 2006b). For Fig. 6, the assay was performed in essentially the
same way, but with differences in the plates, some of the wash
solutions, and the secondary antibody and detection chemistry. Spe-
ciﬁcally, the EBOV antigen was coated onto ﬂat bottom Immulux HB
plates (Dynex Technologies, Chantilly, VA). The coated plates were
washed ﬁve times with phosphate buffered saline (Invitrogen) con-
taining 20% Tween-20 (PBST), incubated for 1 h at 37 °C with blocking
buffer composed of phosphate buffered saline with 5% nonfat drymilk
(Nestle, Solon, OH) and 1% bovine serum albumin fraction V (Roche
USA, Indianapolis, IN), and washed as above. Various dilutions of
guinea pig serum samples in blocking bufferwere added and the plates
were incubated for 1 h at 37 °C and washed as above. Next, 50 μl of
1:500 dilution of alkaline phosphatase-conjugated goat anti-guinea
pig IgG antibodies (Antibodies Incorporated, Davis, CA) in blocking
buffer were added, incubated for 1 h at 37 °C, and washed as above. To
develop the plates, 100 μl per well of Alkaline Phosphatase Yellow
(pNPP) Liquid Substrate System for ELISA (Sigma-Aldrich, St. Louis,
MO) was added, the plates were incubated 20 min at room tem-
perature, and the reactionwas stopped by adding 50 μl per well of 1 N
sodium hydroxide. Optical density was determined at 405 nm.
Statistical analysis of data
Differences were evaluated by Student's T-test and considered
signiﬁcant when Pb0.05. Data are shown as means±SE of the mean.
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